RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

[1]  A. Zelenetz,et al.  Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  J. Flowers,et al.  Origins and geographic diversification of African rice (Oryza glaberrima) , 2018, bioRxiv.

[3]  M. D. Den Boer,et al.  Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients , 2016, Haematologica.

[4]  O. Haas,et al.  Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia , 2016, Leukemia.

[5]  R. Pieters,et al.  Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Loh,et al.  Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia , 2016, Proceedings of the National Academy of Sciences.

[7]  M. D. Den Boer,et al.  Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. , 2016, Blood.

[8]  E. Boerwinkle,et al.  dbNSFP v3.0: A One‐Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice‐Site SNVs , 2016, Human mutation.

[9]  M. Loh,et al.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. , 2015, Blood.

[10]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[11]  A. Borkhardt,et al.  Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients. , 2015, Leukemia research.

[12]  Thomas Zichner,et al.  Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options , 2015, Nature Genetics.

[13]  K. Coombes,et al.  Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. , 2015, Cancer cell.

[14]  B. Johansson,et al.  The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia , 2015, Nature Genetics.

[15]  O. Haas,et al.  KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia , 2015, Leukemia.

[16]  Heidi Ledford.  Cancer: The Ras renaissance , 2015, Nature.

[17]  E. Cuppen,et al.  Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance , 2015, Haematologica.

[18]  Jing Ma,et al.  Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia , 2015, Nature Communications.

[19]  Cheng Cheng,et al.  The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias , 2015, Nature Genetics.

[20]  C. Pui.  Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia , 2015, Frontiers of Medicine.

[21]  S. Lowe,et al.  Preclinical efficacy of MEK inhibition in Nras-mutant AML. , 2014, Blood.

[22]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[23]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[24]  Thomas Knight,et al.  Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting , 2014, Front. Oncol..

[25]  D. Esposito,et al.  Dragging ras back in the ring. , 2014, Cancer cell.

[26]  C. Eckert,et al.  Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. , 2013, Blood.

[27]  R. Kuiper,et al.  B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Specific Copy Number Alterations Are Unique For Progressive Pediatric Chronic Myeloid Leukemia (CML): A Large Cohort Study , 2013 .

[28]  W. Evans,et al.  Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. , 2013, Blood.

[29]  Ariana Peck,et al.  Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers , 2013, Nature.

[30]  C. Pui,et al.  A 50-year journey to cure childhood acute lymphoblastic leukemia. , 2013, Seminars in hematology.

[31]  R. Stam,et al.  Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants , 2013, Haematologica.

[32]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[33]  R. Pieters,et al.  High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation , 2013, Leukemia.

[34]  S. Larson,et al.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.

[35]  M. Morgan,et al.  Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. , 2013, The Lancet. Oncology.

[36]  Robert Huether,et al.  The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.

[37]  Martin Schumacher,et al.  Competing Risks and Multistate Models , 2012, Clinical Cancer Research.

[38]  K. Shannon,et al.  Targeting oncogenic Ras signaling in hematologic malignancies. , 2012, Blood.

[39]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[40]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[41]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[42]  Daniela Cilloni,et al.  Molecular Pathways: BCR-ABL , 2011, Clinical Cancer Research.

[43]  Heng Li,et al.  A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data , 2011, Bioinform..

[44]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[45]  Michael N. Edmonson,et al.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[46]  M. D. Den Boer,et al.  The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97) , 2011, Haematologica.

[47]  A. Verma,et al.  Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. , 2011, Journal of Clinical Oncology.

[48]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[49]  Hein Putter,et al.  mstate: An R Package for the Analysis of Competing Risks and Multi-State Models , 2011 .

[50]  B. Johansson,et al.  Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations , 2010, Leukemia.

[51]  S. Grant,et al.  MEK Inhibitors Potentiate Dexamethasone Lethality in Acute Lymphoblastic Leukemia Cells through the Pro-apoptotic Molecule BIM , 2009, Leukemia.

[52]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[53]  A. Hall,et al.  Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. , 2008, Cancer research.

[54]  X. Shu,et al.  RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia , 2004, Leukemia.

[55]  M. D. Boer,et al.  Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  G. Daley,et al.  Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. , 2001, Blood.

[57]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[58]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[59]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[60]  R. Pieters,et al.  In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia , 1997 .

[61]  R. Pieters,et al.  In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. , 1995, Blood.

[62]  C. Sawyers,et al.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene , 1995, The Journal of experimental medicine.

[63]  F. McCormick,et al.  Analysis of RAS oncogene mutations in human lymphoid malignancies. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Graham-Pole,et al.  Leukaemia in childhood. , 1971, Nursing mirror and midwives journal.

[65]  Tord Høivik,et al.  A program , 1971 .

[66]  R. Sullivan,et al.  Achievements and challenges of molecular targeted therapy in melanoma. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[67]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[68]  R. Pieters,et al.  In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. , 1997, Blood.